This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Fluidigm And NanoString Agree To Litigation Settlement

Stocks in this article: FLDM

Fluidigm Corporation (NASDAQ:FLDM) and NanoString Technologies, Inc. (NASDAQ:NSTG) have agreed to settle lawsuits filed by Fluidigm against NanoString. The terms of the settlement require NanoString to, among other things, remove all references – from its marketing materials, website, and promotional activities – to a single-cell comparison study comparing Fluidigm and NanoString single-cell products, as well as recall and destroy all materials related to and/or based on the study.

“We believe in fair competition and providing researchers with the most accurate information possible so they can make informed decisions about which tools will help them unlock the mysteries of single-cell biology. We believe the Fluidigm BioMark™ HD System provides the most robust, sensitive instrumentation for single-cell gene expression analysis on the market today. When NanoString mischaracterized the capabilities of the BioMark HD System, we were compelled to take action to ensure such improper activity stopped,” said Gajus Worthington, President and Chief Executive Officer of Fluidigm. “We are happy that NanoString has agreed to remove, recall, and destroy the materials in question and take additional corrective measures so that we can each return to properly promoting our respective products’ attributes in the marketplace and helping our customers conduct great research,” Worthington concluded.

Fluidigm’s initial lawsuit against NanoString alleged false advertising, unfair competition, and unlawful trade practice in violation of the Lanham Act and corresponding sections of the California Business & Professional Code. The complaint was filed on November 6, 2012 in federal district court in the Northern District of California. Fluidigm subsequently filed a related case in Singapore.

Fluidigm had charged that in certain advertising and associated campaigns in the single-cell market, NanoString improperly claimed it had conducted a study showing that its nCounter Assay is more robust and sensitive than Fluidigm’s BioMark HD System for single-cell gene expression analysis.

NanoString based these claims on what it described as a “head to head” comparison of the nCounter system and Fluidigm BioMark HD System, but in fact this study was not a true head-to-head comparison study and Fluidigm believes was not conducted in a scientifically valid manner. The testing was performed by different laboratories, at different times, and using different sample preparation protocols. Among other differences, NanoString used a two-step sample preparation protocol for its nCounter system, while disadvantaging the Fluidigm BioMark HD System with a non-preferred one-step protocol.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs